ACM
FATE icon

Aquilo Capital Management’s Fate Therapeutics FATE Stock Holding History

Aquilo Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-72,273
Closed -$1.41M – 15
2019
Q4 		$1.41M Hold
72,273
– – 0.53% 11
2019
Q3 		$1.12M Sell
72,273
-529,823
-88% -$10.2M 0.79% 11
2019
Q2 		$12.2M Sell
602,096
-95,000
-14% -$1.71M 4.24% 7
2019
Q1 		$12.2M Hold
697,096
– – 5.42% 7
2018
Q4 		$8.94M Sell
697,096
-287,500
-29% -$4.01M 4.33% 6
2018
Q3 		$16M Buy
984,596
+404,367
+70% +$4.78M 6.71% 4
2018
Q2 		$6.58M Buy
+580,229
New +$6.39M 5.43% 6

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Aquilo Capital Management's FATE Position: Q1 2020 in Review

Aquilo Capital Management sold out of Fate Therapeutics (FATE) in Q1 2020, closing a stake of 72,273 shares — an estimated $1.41M sold.

Aquilo Capital Management first reported a position in FATE in Q2 2018 and held it in 7 quarters. The position peaked at $16M in Q3 2018. 156 funds tracked by Wall St. Rank hold FATE as of Q1 2020.

  • Aquilo Capital Management reported no remaining Fate Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Aquilo Capital Management sold 72,273 Fate Therapeutics shares in Q1 2020, an estimated $1.41M.
  • Aquilo Capital Management first reported a position in Fate Therapeutics in Q2 2018 and held it in 7 quarters.
  • Aquilo Capital Management's Fate Therapeutics position peaked at $16M in Q3 2018.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2020.

Based on Aquilo Capital Management's 13F filing for Q1 2020, filed 15 May 2020.